Andrx lovastatin XL approved
Executive Summary
Andrx plans to launch extended-release Altocor (lovastatin) in the third quarter with a 280-rep sales force. The product was approved June 26. "At steady state in humans, the bioavailability of lovastatin, following the administration of Altocor, was 190% compared to lovastatin immediate-release," labeling states. The NDA for the cholesterol-lowering agent was filed March 29, 2001 (1"The Pink Sheet" April 2, 2001, p. 15)...
You may also be interested in...
Andrx To Launch Lovastatin XL In 2002 With 150-Rep Sales Force
Andrx plans to launch extended-release lovastatin in 2002 for hyperlipidemia with three years of exclusivity, President Elliot Hahn, PhD, announced March 28 at the Banc of America Securities Healthcare Conference in Las Vegas.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.